Eupraxia Pharmaceuticals Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2022 | $-14.4M | $-14.4M | — | $1.4M |
| FY2023 | $-20.7M | $-20.7M | — | $1.4M |
| FY2024 | $-30.0M | $-30.0M | — | $3.2M |
| FY2025 | $-28.6M | $-28.6M | — | $8.8M |
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2022 | $-14.4M | $-14.4M | — | $1.4M |
| FY2023 | $-20.7M | $-20.7M | — | $1.4M |
| FY2024 | $-30.0M | $-30.0M | — | $3.2M |
| FY2025 | $-28.6M | $-28.6M | — | $8.8M |